DOI 10.1016/j.ijrobp.2025.10.029
Nimotuzumab Plus Image-Guided Radiation Therapy for Elderly Patients with Locally Advanced Cervical Squamous Cell Carcinoma: Interim Analysis of a Prospective Multicenter Phase II Trial.
Аннотация
PURPOSE: Elderly patients with locally advanced cervical squamous cell carcinoma (LACSCC) generally have fewer therapeutic choices. Nimotuzumab, as an epidermal growth factor receptor-targeted humanized monoclonal antibody, has low toxicity, and shown antitumor efficacy in cervical cancer in preliminary study. Therefore, we wanted to explore efficacy and safety of nimotuzumab and image-guided radiation therapy for elderly patients with LACSCC.
METHODS AND MATERIALS: This is a prospective, multicenter, open-label, single-arm, and phase II trial. LACSCC patients aged ≥ 65 years not receiving chemotherapy were enrolled. All of the patients received intensity-modulated radiation therapy and image-guided brachytherapy. Nimotuzumab was administration of 200 mg once a week for 6 weeks. Disease-free survival (DFS) is the primary endpoint. Secondary endpoints included overall survival (OS), complete response rate, objective response rate, and safety.
RESULTS
From November 2021 to January 2023, a total of 118 elder patients with stage IB3-IVA were enrolled. The median follow-up was 24 months (95% CI: 21.78, 25.53). The complete response rate was 61.86% (95% CI, 0.53-0.71), objective response rate was 91.53% (95% CI, 0.85-0.96). The 1 year-DFS and 2 year-DFS were 92.42% (95% CI, 85.40-96.14) and 84.61% (95% CI, 75.07-90.72), respectively, the median DFS was 36.99 months (95% CI, NA, NA). The 1 year-OS was 96.19% (95% CI, 90.15-98.55), 2 year-OS was 88.22% (95% CI, 78.87-93.60), the median OS was not reached. The most common grade 3 adverse events included leukopenia (4/30.77%), neutropenia (3/23.08%), lymphopenia (2/15.38%), diarrhea (1/7.69%), and anemia (3/23.08%). No drug-related severe adverse events or deaths were recorded.
CONCLUSIONS
Among elderly LACSCC patients, nimotuzumab plus image-guided radiation therapy and brachytherapy was well tolerated and indicated promising clinical survival benefits. The robustness of efficacy and toxicity results might provide a novel treatment option for this population.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.